Osteoporosis and sarcopenia: the connections

Umberto Tarantino · Jacopo Boldi · Montina Celli · Cecilia Rao · Federico Maria Liuni · Riccardo Iundisi · Elena Gasbarra

Received: 1 June 2013 / Accepted: 12 July 2013 / Published online: 18 September 2013
© Springer International Publishing Switzerland 2013

Abstract Osteoporosis and sarcopenia are the most frequent musculoskeletal disorders affecting older people. Osteoporosis is a widespread disorder affecting millions of individuals of all ethnic backgrounds worldwide, particularly among older women. It is characterized by reduced bone mass and microarchitectural deterioration of bone tissue, with an increased risk of fracture. Sarcopenia is considered to be one of the major factors responsible for functional limitations and motor dependency in elderly persons. In age-related muscle atrophy, a decrease in muscle fiber size and number, and a preferential loss of type II fibers have been reported. A decrease in the circulating levels of specific hormones (e.g., estrogen, testosterone, growth hormone, and insulin-like growth factor-1) has been shown to be associated with sarcopenia and this appears to play an important role in its pathogenesis.

Keywords Sarcopenia · Osteoporosis · Frailty syndrome

Introduction

The increased longevity of the population is inevitably causing a rise in the incidence of chronic degenerative diseases that affect elderly people, especially those related to the musculoskeletal system. Osteoporosis and sarcopenia are essential components of frailty syndrome, a pathology that jeopardizes the health of older adults, decreasing their quality of life [1, 2]. According to Clegg [3], the condition of frailty, which is typical of older adults, can have its origin in the combination of different pathological conditions. This is why frailty syndrome is not a specific syndrome, but rather an ever-changing condition, identified by a number of elements on the basis of which Fried et al. [4, 5] conceived the idea of the frailty phenotype. Therefore, understanding the musculoskeletal system is important in the determination of frailty syndrome.

Muscle and bone connection

As muscles become larger and stronger during growth and in response to increased loading, bones should adapt by adding mass, size, and strength. At the age of 50-60 years, muscle mass begins to decrease by roughly 40%, which is equal to 1% every year. This decrease causes a reduction, which can be clinically assessed, of muscle strength and resistance. These findings are typical of sarcopenia, which features a regular decrease in bone mass, and this occurs more rapidly in women than in men [6]. It occurs because the deficit in estrogen has a negative effect on cell turnover of bones from the first year after menopause. At the age of 80 years, osteoporosis and sarcopenia have parallel progress again in a form that can be described as sarco-osteoporosis [7]. In adults, even though there is an initial reduction of muscle mass and strength, bone still receives “efficient” mechanical stimuli that maintain the basic multicellular units (BMUs) in an adapted state. In older adults, where muscle masses atrophy is no longer able to develop huge loading on the bones, the BMUs activate a “druse pattern”, which causes a loss of biomechanical
The loss of biomechanical properties of the bone appears in terms of elastic modulus, resistance, and stiffness. These three parameters, which mirror those discussed above for muscle tissue, are the actual causes of the reduced support function typical of the osteoporotic condition. Between the ages of 30 and 80 years, in cortical bone, the elastic modulus decreases by 8%, its resistance diminishes by 11%, and its stiffness decreases by 34%. In cancellous bone, the elastic modulus decreases by approximately 64%, its resistance diminishes by 68%, and its stiffness can be reduced by up to 70% [16].

Hormonal activity is another important aspect in the regulation of muscle trophism. Growth hormone (GH) of which the second effector is insulin-like growth factor 1 (IGF-1), is one of the main regulators of muscle trophism and muscle fiber survival. A reduction in GH is the cause of types I and II fiber atrophy, which underlies the sarcopenic condition. GH reduction also causes a decrease in calcium release from the sarcoplasmic reticulum, which regulates fiber contractility. Reduced GH secretion has a negative effect on cell proliferation and differentiation of progenitor cells at an osteoblastic level. This is associated with an increase in cellular apoptosis and with changes in mineralization of the organic matrix of the bone.

Osteoporosis-related muscle atrophy shows some similarity with other systemic conditions, such as cachexia, diabetes, and steroid myopathy, in which preferential and diffuse involvement of type II fibers has been described [17-19]. In these chronic conditions, a decrease in the levels of specific hormones causes reduced activation of the IGF-1/P38K/Akt pathway, the major regulator of postnatal growth of muscle. This leads to impaired glucose intake, altered muscle metabolism, and muscle atrophy. IGF-1 exerts its effects through a specific receptor, IGF-1R, which is the most potent natural activators of the PI3K/Akt signaling pathway. Akt, through different downstream mediators, promotes protein synthesis and retards protein degradation by regulating the expression of various atrogens [20, 21]. In addition, IGF-1 is able to counteract the effects of myostatin, a member of the transforming growth factor-β family involved in muscle atrophy. Moreover, because IGF-1/P38K/Akt controls glucose uptake in skeletal muscle [20], its downregulation can affect mainly glycolytic fibers (type II), whereas oxidative fibers (type I) tend to be more resistant to atrophy, because of their capacity for using other substrates than glucose to produce energy.

Our experience

In a study published by our research group in 2012, we showed that osteoporosis is associated with preferential